(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs - 2AI’s errors may be impossible to eliminate – what that means for its use in health care
- 3The Force of Systems administration: Individual Examples of overcoming adversity
- 4How do my eyes adjust to the dark and how long does it take?
- 5Startled Venezuelans express relief but also fear after Maduro arrest
- Opening Achievement: 8 Methodologies for Compelling Using time productively
- Limited Rain Chances in Brazil Boost Coffee Prices
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- You finally got a doctor's appointment. Here's how to get the most out of it
- Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- Telescope in Chile captures stunning new picture of a cosmic butterfly
- Vote In favor of Your Favored Sort Of Bevarage
- Astronauts head home early after medical issue
